PERIOGARD MOUTHWASH

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

download SPC (SPC)
23-08-2017

active_ingredient:

CHLORHEXIDINE GLUCONATE

MAH:

COLGATE-PALMOLIVE CANADA INC

ATC_code:

A01AB03

INN:

CHLORHEXIDINE

dosage:

0.12%

pharmaceutical_form:

MOUTHWASH

composition:

CHLORHEXIDINE GLUCONATE 0.12%

administration_route:

BUCCAL

units_in_package:

473ML

prescription_type:

Prescription

therapeutic_area:

MISCELLANEOUS ANTI-INFECTIVES

leaflet_short:

Active ingredient group (AIG) number: 0107629007; AHFS:

authorization_status:

CANCELLED POST MARKET

authorization_date:

2022-03-30

SPC

                                _Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE ORAL RINSE
Chlorhexidine Gluconate 0.12% Oral Rinse Liquid, USP
0.12% Chlorhexidine Gluconate Antigingivital Oral Rinse
Colgate-Palmolive Canada Inc.
Two Morneau Shepell Centre, 5
th
Floor,
895 Don Mills Road,
Toronto, Ontario
M3C 1W3
Submission Control No.: 207101
Date of Preparation:
August 17, 2017
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
................................................................3
INDICATIONS AND CLINICAL USE
......................................................................3
CONTRAINDICATIONS
.........................................................................................3
WARNINGS AND PRECAUTIONS
........................................................................4
ADVERSE
REACTIONS.........................................................................................6
DOSAGE AND ADMINISTRATION
........................................................................6
OVERDOSAGE
.....................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
........................................................8
STORAGE AND STABILITY
..................................................................................9
SPECIAL HANDLING INSTRUCTIONS
................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................10
PART II: SCIENTIFIC INFORMATION
..........................................................................11
PHARMACEUTICAL
INFORMATION..................................................................11
CLINICAL TRIALS
................................................................................................12
DETAILED PHARMACOLOGY
............................................................................13
MICROBIOLOGY
..............................
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 17-08-2017